Table 3:
DICOM attributes proposed for addition to HP 13C MRI study data. This captures the majority but not all the desired parameters listed in Table 1.Note that the “Contrast/Bolus Ingredient” attributes listed can include more than one entry to support multiple simultaneously polarized HP 13C agents17 such as pyruvate/urea3,14. The proposed 13C naming conventions are in a style that is consistent with the style used for PET in DICOM.
| TAG | VR | Attribute Name | 1H MRI Example Values | HP 13C Description | HP 13C Example Values |
|---|---|---|---|---|---|
| (0018,0010) | LO | Contrast/Bolus Agent | CC MAGNEVIST ORAL & OMNIPAQUE |
HP 13C agent(s) injected | HYPERPOLARIZED [1–13C]PYRUVATE HYPERPOLARIZED [2–13C]PYRUVATE HYPERPOLARIZED [1–13C]PYRUVATE + [13C,15N]-UREA |
| (0018,1040) | LO | Contrast/Bolus Route | Administration route of contrast agent | IV | |
| (0018,1041) | DS | Contrast/Bolus Volume | Injected volume (mL) | ||
| (0018,1042) | TM | Contrast/Bolus Start Time | Define start of injection relative to data acquisition (Not DICOM compliant) Start Time in HHMMSS.FFFFFF (DICOM compliant) |
||
| (0018,1047) | DS | Contrast/Bolus Flow Duration | Total injection duration [s] | ||
| (0018,1048) | CS | Contrast/Bolus Ingredient | IODINE BARIUM GADOLINIUM CARBON DIOXIDE |
13C enriched compounds | [1-^13^C]PYRUVATE [2-^13^C]PYRUVATE [^13^C,^15AN]UREA [1-^13^C]ALPHA- KETOGLUTARATE |
| (0018,1049) | DS | Contrast/Bolus Ingredient Concentration | Concentration of each 13C compound [mg/mL] | ||
| (0400,0550) | SQ | Modified Attributes Sequence | Store prior versions of an attributes that were removed or modified | ||
| (0400,0562) | DT | Attribute Modification DateTime | Tracked Date and Time when attributes were modified | ||
| (0400,0563) | LO | Modifying System | Describes what modified the attributes | SIVIC-HP_agent_DICOM_tool.py |